Check out this compilation of our ACR17 Day 2 videocasts merged into a one hour podcast !
Dr. Janet Pope: JAK 2 Inhibitor Controversy
Dr. Janet Pope talks about JAK 2 inhibitors and increased VTE as presented at the ACR/ARHP Annual Meeting in San Diego.
Dr. Paul Sufka: Managing Online Reputation and Distributing Research
Dr. Paul Sufka shares tips from a session for physicians and scientists to manage their online reputation and share their research as presented at the ACR/ARHP Annual Meeting in San Diego.
Dr. Ken Saag: Update on Gout Therapy
Dr. Ken Saag discusses gout therapies at the ACR/ARHP Annual Meeting in San Diego.
Dr. Janet Pope: Gout Gamechangers
Dr. Janet Pope discusses three take-home messages from gout studies presented at the ACR/ARHP Annual Meeting in San Diego.
Dr. David Borenstein: Pain Abstracts at ACR 2017
Dr. David Borenstein reviews abstracts in the area of pain in rheumatic diseases as presented at the ACR/ARHP Annual Meeting in San Diego.
Dr. Jack Cush and Dr. Ted Pincus: Damage in Rheumatoid Arthritis
Dr. Jack Cush and Dr. Ted Pincus to discuss damage in RA at the ACR/ARHP Annual Meeting in San Diego.
In the afternoon on Monday, the ACR ran a clinical symposium on gout. One presentation stood out, on “Asymptomatic hyperuricemia” (AH) by M. Pillinger, MD from NYU Medical School. At issue is when should AH be treated. He showed impressive data by Feig, wherein adolescents with hypertension and a high SUA were treated with either placebo or urate lowering therapy (ULT).
Even with currently available treatment modalities, ESRD is a common complication of Granulomatosis with polyangiitis (GPA) occurring in approximately 25% of patients. Transplantation frequently used for ESRD but has not been applied widely in GPA. Current analysis is aimed at evaluation of benefits of transplantation in extending surgical or prisons with GPA comparing to remaining on waiting list.
IgG4 related fibrosis is rare condition with little data available on its diagnosis and treatment.
Dr. David Borenstein: Back Pain
Dr. David Borenstein looks at back pain abstracts at the ACR/ARHP Annual Meeting in San Diego.
Clinical trials remain a challenge in SLE and a number of outcome measures have been used with varying success.Two abstracts in this session sought to address novel ways to assess responses in SLE trials.
On Monday November 11th, Dr. Suleman Bhana, presented Tech Tools for Rheumatologists Version 3.0. Dr.
A high proportion of GPA patients receive pneumocystis prophylaxis, usually with TMP-SMX (Bactrim), and drug interactions are always a concern.
Prof Weyland started by explaining that giant cell arteritis (GCA) and Takayasu Arteritis (TA) are granulomatous forms of arteritis. The age of onset is usually >60 years in GCA and < 40 years in TA, the group in the middle may be a different form of vasculitis based on gene expression studies.
